Detalles de la búsqueda
1.
Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial.
Lancet
; 397(10268): 51-60, 2021 01 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33338437
2.
Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine.
N Engl J Med
; 381(2): 142-149, 2019 07 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31291516
3.
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial.
Headache
; 62(9): 1153-1163, 2022 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36239038
4.
Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial.
Lancet
; 394(10200): 737-745, 2019 08 31.
Artículo
en Inglés
| MEDLINE | ID: mdl-31311674
5.
Testing rimegepant for migraine-time to revise the trial design? - Authors' reply.
Lancet
; 395(10241): 1901-1902, 2020 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32563365
6.
Pain Freedom at 2-8 Hours With Lasmiditan: A Comparison With Rimegepant and Ubrogepant: A Response.
Headache
; 60(10): 2611-2612, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33249583
7.
Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial.
Lancet Neurol
; 22(3): 209-217, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36804093
8.
Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial.
Lancet Neurol
; 22(6): 476-484, 2023 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-37210098
9.
Application of microbial analyses to feeds and potential implications for poultry nutrition.
Poult Sci
; 101(5): 101789, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35346494
10.
Human Milk and Plasma Pharmacokinetics of Single-Dose Rimegepant 75 mg in Healthy Lactating Women.
Breastfeed Med
; 17(3): 277-282, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-35049333
11.
P-Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.
Clin Pharmacol Drug Dev
; 11(7): 889-897, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35304977
12.
Best practices in compound management for preserving compound integrity and accurately providing samples for assays.
J Biomol Screen
; 14(5): 476-84, 2009 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-19483144
13.
Strain-related differences in urine composition of male rats of potential relevance to urolithiasis.
Toxicol Pathol
; 37(3): 293-305, 2009 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-19380840
14.
Viral Drug Resistance Through 48 Weeks, in a Phase 2b, Randomized, Controlled Trial of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir.
J Acquir Immune Defic Syndr
; 77(3): 299-307, 2018 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29206721
15.
Safety, efficacy, and dose response of the maturation inhibitor GSK3532795 (formerly known as BMS-955176) plus tenofovir/emtricitabine once daily in treatment-naive HIV-1-infected adults: Week 24 primary analysis from a randomized Phase IIb trial.
PLoS One
; 13(10): e0205368, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30352054
16.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in antiretroviral-experienced subjects: week 48 analysis of AI438011, a Phase IIb, randomized controlled trial.
Antivir Ther
; 22(3): 215-223, 2017.
Artículo
en Inglés
| MEDLINE | ID: mdl-27922453
17.
Soluble Abeta and cognitive function in aged F-344 rats and Tg2576 mice.
Behav Brain Res
; 173(1): 62-75, 2006 Oct 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-16828889
18.
Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy.
Exp Clin Psychopharmacol
; 14(1): 42-51, 2006 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-16503704
19.
Efficacy, safety, bone and metabolic effects of HIV nucleoside reverse transcriptase inhibitor BMS-986001 (AI467003): a phase 2b randomised, controlled, partly blinded trial.
Lancet HIV
; 3(1): e13-22, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26762988
20.
Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial.
Lancet HIV
; 2(10): e427-37, 2015 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26423650